News und Analysen
EQS-News: Drägerwerk AG & Co. KGaA: Dräger increases net profit in fiscal year 2024 and raises dividend
EQS-News: Biotest AG increases sales by 6% in financial year 2024
EQS-News: Sartorius AG - Resolutions of the Annual General Meeting
Is Merck Stock a Bargain Buy?
Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. While there are concerns about its patent losses in the future, its sales are still
EQS-News: RHÖN-KLINIKUM AG once again reports a successful financial year – CEO Prof. Kaltenbach leaves the Board of Management as planned
2 Beaten-Down Stocks to Buy on the Dip
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are
EQS-News: STRATEC ANNOUNCES CHANGES TO 2025 FINANCIAL CALENDAR
EQS-News: STRATEC RECEIVES VALIDATION OF ITS CLIMATE TARGETS FROM THE SCIENCE BASED TARGETS INITIATIVE (SBTi)
EQS-Adhoc: Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.
EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share
EQS-News: ZEISS VISUMAX 800 with SMILE pro software receives approval in China
EQS-Adhoc: Biotest AG publishes preliminary business figures - 2024 forecasts partially exceeded
EQS-News: Evotec announces change in Management Board
EQS-News: Gerresheimer delivers solid results in the financial year 2024 despite market headwinds
Is Merck Stock a Buy?
It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates with
EQS-News: Sartorius releases Annual Report for 2024
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Most companies don't survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull it off. These are the kinds of stocks long-term investors will often
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first three months of 2024/25
EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition
Better High-Yield Dividend Stock: Pfizer vs. Merck
Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (NYSE: MRK) that
EQS-Adhoc: Gerresheimer AG confirms discussions with private equity investors on potential takeover offer
EQS-News: The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share
Merck (MRK) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Merck (NYSE: MRK)Q4 2024 Earnings CallFeb 04, 2025, 9:00 a.m. ET
Operator
Source Fool.com
Why Merck Stock Is Plummeting Today
Shares of Merck (NYSE: MRK) were trading lower on Tuesday. The company's stock had lost 10.1% as of 2 p.m. ET, but was down as much as 12.5% earlier in the day. The drop comes as the S&P 500 gained